Clinical trials: Patients With Tumor
Lenvatinib Treatment
Using Chronobiology to Improve Lenvatinib Efficacy
The goal of this proof-of-concept clinical trial is to assess the efficacy and safety of chronobiology implementation into lenvatinib treatment regimens of thyroid cancer patients, via a mobile application.
- Trial name
- NCT06321120
- Testing
- variability-based lenvatinib regimen
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Hadassah Medical Organization
Pancreatic Cancer
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
This study will evaluate efficacy, safety and tolerability of Avastin versus placebo added to a chemotherapeutic regimen in patients with metastatic pancreatic cancer.
- Trial name
- NCT01214720
- Testing
- bevacizumab [Avastin]
- Where
- 101 sites in Australia, Austria and 19 more
- Volunteers
- 607 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, T-Cell, Cutaneous
CPG 7909 in Patients With Cutaneous T-Cell Lymphoma
To assess the effect of CPG 7909 Injection on Cutaneous T-cell lymphoma and the safety of CPG 7909 Injection in patients with this cancer.
- Trial name
- NCT00043420
- Testing
- PF-3512676
- Volunteers
- 42 people
- Sponsor
- Pfizer
Chronic Myeloproliferative Disorders, Leukemia
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00296023
- Testing
- anti-thymocyte globulin, filgrastim, therapeutic allogeneic lymphocytes
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of California, San Francisco
Lymphoma
DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701
This research trial studies deoxyribonucleic acid (DNA) analysis in predicting response to antibody therapy in patients with follicular lymphoma treated on clinical trials Cancer and Leukemia Group B (CALGB)-50402 or CALGB-50701.
- Trial name
- NCT01057459
- Testing
- laboratory biomarker analysis
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Glioblastoma, Gliosarcoma
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
Paclitaxel is among the most active agents against glioblastoma in preclinical models. However, its clinical use has been hampered by the blood-brain barrier (BBB).
- Conditions
- Glioblastoma, Gliosarcoma, GBM, Glioblastoma Multiforme
- Trial name
- SC9/ABX (NCT04528680)
- Testing
- Sonication for opening of blood-brain barrier, Chemotherapy, albumin-bound paclitaxel, Chemotherapy, carboplatin
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Northwestern University
Myeloma Multiple, Myeloma
Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
The purpose of this study is to determine the efficacy and safety of investigational combination therapy of Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd) for patients with relapsed/refractory multiple…
- Conditions
- Myeloma Multiple, Myeloma, Refractory Multiple Myeloma
- Trial name
- ClaSPd (NCT04843579)
- Testing
- Selinexor, Clarithromycin, Pomalidomide
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer (Adenocarcinoma)
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
This is a Phase I/II trial evaluating the effectiveness of adding neoadjuvant HDR-B prior to RALP for HR-PCa patients with selective AAB for decipher high risk or pathologically node positive patients.
- Trial name
- NCT07182279
- Testing
- Brachytherapy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- The Methodist Hospital Research Institute
Anastomotic Leak
PARLAR-02 Trial：Modified Transanal Drainage Tube Use for Preventing Anastomotic Leakage
Surgical resection remains the primary treatment for rectal cancer, but the postoperative incidence of anastomotic leakage (AL) is relatively high.
- Trial name
- NCT07036588
- Testing
- Modified Transanal Drainage Tube
- Where
- China
- Volunteers
- 968 people
- Sponsor
- Third Military Medical University
Malignant Lymphoma
Phase I Study of Mitoxantrone Hydrochloride Liposome Injection
The purpose of this study is to determine the maximum tolerated dose,the safety and effectiveness of Mitoxantrone Hydrochloride Liposome Injection.
- Trial name
- NCT02131688
- Testing
- Mitoxantrone Hydrochloride Liposome
- Where
- China
- Volunteers
- 30 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Esophageal Cancer
Simultaneous Integrated Boost (SIB) in Esophageal Cancer
The goal of this clinical research study is to find the highest tolerable dose of radiation that can be given in combination with chemotherapy in patients with esophageal cancer that cannot be removed by surgery.
- Trial name
- NCT01102088
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
NSCLC
Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer
Non-small-cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations are exquisitely sensitive to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) which is widely…
- Trial name
- NCT02272127
- Testing
- icotinib
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Brain Metastases
Phase 1 Trial for Tumor Treating Field for Drug/Radiation Resistant Brain Metastases
Brain metastasis is a very common disease with poor prognosis, 20% cancer will develop brain metastases(BM), up to 40% by autopsy.
- Trial name
- NCT04967027
- Testing
- ASCLU-300 TTF
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Xiangya Hospital of Central South University
Carcinoma, Renal Cell
An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma
Purpose of the study: The purpose of this study is to make sorafenib available for patients with advanced Renal Cell Carcinoma, who have failed prior systemic therapy for advanced disease (i.e.
- Trial name
- NCT00492986
- Testing
- Nexavar (Sorafenib, BAY43-9006)
- Where
- 33 sites in Belgium, Denmark and 9 more
- Volunteers
- 1,150 people
- Sponsor
- Bayer
Candidiasis, Fungal Infection
PTX3-targeted Antifungal Prophylaxis
This is a prospective genetically-stratified randomized double-blind event-driven multicentre clinical trial to assess the efficacy of posaconazole-based antifungal prophylaxis allocation strategies for patients with acute…
- Conditions
- Candidiasis, Fungal Infection, Acute Myeloid Leukemia, Genetic Predisposition
- Trial name
- PTX3AML (NCT03828773)
- Testing
- Posaconazole, Fluconazole
- Where
- 9 sites in Belgium, France and 1 more
- Volunteers
- 410 people
- Sponsor
- Bochud Pierre-Yves
Breast Cancer
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
This research study is studying a drug called GDC-0084 as a possible treatment for HER2-Positive Breast Cancer. The drugs involved in this study are: GDC-0084 Trastuzumab (Herceptin®)
- Trial name
- NCT03765983
- Testing
- Trastuzumab, GDC-0084
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Dana-Farber Cancer Institute
Squamous NSCLC
Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)
This is an open-label, first-in-human, dose escalation study of CV09070101 mRNA (CVHNLC) in patients with metastatic Squamous Non-Small-Cell Lung Cancer (sqNSCLC).
- Trial name
- NCT07073183
- Testing
- CV09070101 mRNA vaccine (CVHNLC) 50 µg, CV09070101 mRNA vaccine (CVHNLC) 100 µg, CV09070101 mRNA vaccine (CVHNLC) 200 µg
- Where
- 13 sites in United States, France and 1 more
- Sponsor
- CureVac
GCT, Germ Cell Tumor
Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin.
This trial is a prospective single arm intervention study, conducting clinical research on marketed drugs. Adverse drug reactions are controllable and the risk is low, with an estimated total of 40 cases.
- Conditions
- GCT, Germ Cell Tumor, Central Malignant Germ Cell Tumor
- Trial name
- NCT07188441
- Testing
- Teniposide Injection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chengcheng Guo
Pancreatic Cancer
Evaluation of GEMCITEST in Patients With Pancreatic Cancer and Treated by Chemotherapy
Pancreatic cancer has a 5-year overall survival rate around 5%. It is the 6th most common cancer in France (11 600 new annual cases in 2012) and the 4th leading cause of cancer deaths in France and Europe.
- Trial name
- GEMCIPANC (NCT03599154)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Georges Francois Leclerc
Resectable Esophageal Cancer
Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer
Despite the availability of several preoperative diagnostic techniques, accurate pretreatment staging of esophageal cancer (EC) remains challenging.
- Trial name
- NCT01858805
- Testing
- esophagectomy
- Where
- Germany
- Volunteers
- 123 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.